LVTX

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-83.2K ExitQ4 2025 $83k -- $1.74
Ken GriffinCitadel Advisors $-8.7K TrimQ3 2025 $8.7k -- $1.74
Robert BruceBruce & Co $-688.9K ExitQ3 2025 $689k -- $1.74
Robert BruceBruce & Co $26.1K AddQ2 2025 $26k -- $1.74
Ken GriffinCitadel Advisors $21.9K AddQ2 2025 $22k -- $1.74
Robert BruceBruce & Co $-70.5K TrimQ1 2025 $71k -- $1.74

Insider Trades

Name	Value	Action	Price	Current Price
Cooperatieve Gilde Healthcare IV U.A.10 Percent Owner $2M1.2M shares SellOct 17, 2025 $1.47 $1.74
Cooperatieve Gilde Healthcare IV U.A.10 Percent Owner $1M690.2k shares SellOct 16, 2025 $1.49 $1.74
Cooperatieve Gilde Healthcare IV U.A.10 Percent Owner $343k227.3k shares SellOct 14, 2025 $1.51 $1.74
Cooperatieve Gilde Healthcare IV U.A.10 Percent Owner $73k47.7k shares SellOct 13, 2025 $1.54 $1.74
Cooperatieve Gilde Healthcare IV U.A.10 Percent Owner $77k49.9k shares SellOct 10, 2025 $1.55 $1.74
Cooperatieve Gilde Healthcare IV U.A.10 Percent Owner $75k48.2k shares SellOct 9, 2025 $1.56 $1.74

Trade LVTX

About LAVA Therapeutics N.V.

LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.

CEO: Stephen Allen Hurly
IPO Date: Mar 26, 2021

Market Data

Open: $1.74
High: $1.74
Low: $1.74
Volume: 285.5K
52W High: $2.00
52W Low: $0.85

Valuation

Market Cap: $45.8M
Enterprise Value: -$3.9M

Financials

Free Cash Flow: -$19.6M
Revenue: $12M
Net Income: -$25.1M
Cash: $35M
Debt: $5.3M

Events

EarningsNov 6

EPS est. -0.23 · actual -0.27